FRANKFURT, Kelemānia–(BUSINESS WIRE)–Merz Therapeutics, he alakaʻi ma ke kahua o nā neurotoxins a me kahi ʻoihana ma lalo o ka Merz Group, a me Teijin Pharma Limited, ka hui kumu o ka ʻoihana mālama ola o Teijin Group, i hoʻolaha pū ʻia i kēia lā ua lanakila ʻo Teijin Pharmaceuticals. ʻae ʻia mai ke Kuhina Ola, Labour a Welfare (MHLW) e hoʻohana i ka Xeomin® (incobotulinumtoxinA) i loko o 50, 100 a i ʻole 200 mau ʻāpana o ka intramuscular injection no ka mālama ʻana i nā spasms o nā lālā haʻahaʻa.
ʻO ka spasm o nā lālā haʻahaʻa kahi hōʻailona o ka maʻi neuron motor luna, ka mea i hōʻike nui ʻia e ka hoʻonui ʻana i ka ʻiʻo o nā lālā a me ka hauʻoli nui o ka stretch reflex ma ke ʻano he sequelae o ka hahau.ʻO nā hōʻailona nui ka paʻakikī i ka hele maʻamau a me ka piʻi ʻana o ka hāʻule ma muli o ka paʻa ʻole o ke kumu, paʻakikī a keʻakeʻa paha i nā hana i kēlā me kēia lā.ʻO ka hoʻomaʻamaʻa maʻamau no nā wāwae wāwae e pili ana i ka hoʻoponopono kino a me ka hoʻohana ʻana i nā mea hoʻomaha ʻiʻo waha a i ʻole nā neuromuscular blockers, e like me ka botulinum toxin type A.
Ua ʻōlelo ʻo Stefan Brinkmann, Luna Hoʻokele o Merz Therapeutics: "ʻO ka ʻae ʻia e hōʻailona i kahi mea nui no Merz Therapeutics a ʻo ia ka hopena o kā mākou hui pū ʻana me Teijin Pharmaceuticals.Manaʻo mākou e hoʻolauna maikaʻi kā mākou mau hoa i kēia hōʻailona spasticity koʻikoʻi i nā kauka Iapana a me nā maʻi. "
ʻO Kauka Stefan Albrecht, Hope Pelekikena Nui o Global R&D, Merz Therapeutics: "ʻO kēia hoʻonui lepili ma Iapana kahi hiʻohiʻona maikaʻi loa o nā pōmaikaʻi a Xeomin ® i hāʻawi i nā maʻi he nui me ka spasticity post-stroke.Hiki i nā kauka ke koho i kēia manawa e mālama i ka spasticity haʻahaʻa a me luna, a i ʻole hiki ke maʻalahi e like me ka mea e pono ai E hoʻopili pono i kēlā me kēia.Haʻaheo mākou i kēia hoʻokō, ʻoi aku ka maikaʻi o ka launa pū ʻana me kā mākou hoa Teijin. "
Ua ʻōlelo ʻo Pelekikena ʻo Teijin Pharmaceutical ʻo Ichiro Watanabe: "Ke hāʻawi nei ʻo Teijin Pharmaceutical i nā ʻano lāʻau lapaʻau like ʻole, me ka mālama ʻana i ka osteoporosis a me nā mea lapaʻau, e like me ke kani ʻana o ke kani ʻana i ka ʻōnaehana hoʻōla fracture no nā maʻi me nā maʻi musculoskeletal.I ka pane ʻana i nā loli demographic a me ka hoʻonui ʻana i ka ʻike olakino , Ke hoʻolaha nei mākou i nā lāʻau lapaʻau maikaʻi a me nā hoʻonā hou, me ka hoʻokō ʻana i kahi kaiāulu hoʻomau.Ke hoʻomau nei ʻo Teijin Pharmaceuticals i ka hoʻomaikaʻi ʻana i ka maikaʻi o ke ola (QOL) o nā maʻi ma o ka hāʻawi ʻana i nā koho lapaʻau hou no nā maʻi me nā pono ʻole.”
Hoʻomaʻamaʻa maikaʻi ʻo Xeomin® i nā hopena o ke aʻalolo cholinergic peripheral ma o ka hoʻonāwaliwali ʻana i ka ʻoki ʻana o nā ʻiʻo manawaleʻa, a hoʻomaha i ka ʻāʻī o ka ʻiʻo ma ke kāohi ʻana i ka hoʻokuʻu ʻana o kahi neurotransmitter i kapa ʻia acetylcholine.ʻO ka neurotoxin i hoʻomaʻemaʻe maikaʻi ʻia ʻo ia wale nō ka mea hana ma Xeomin®.Hana ʻia ia ma ka wehe ʻana i nā protein paʻakikī mai ke ʻano A botulinum toxin i hana ʻia e Clostridium botulinum me ka hoʻohana ʻana i ka ʻenehana hoʻomaʻemaʻe i hoʻomohala ʻia e Merz Pharma GmbH & Co. KGaA.ʻO ka nele o nā protein paʻakikī e hiki ai iā Xeomin® ke hōʻemi i ka hana ʻana o nā antibodies neutralizing i hiki ke hōʻemi i ka pono.Ua ʻike ʻia ka hoʻomaikaʻi koʻikoʻi o ka pālākiō ashworth scale (MAS) i hoʻololi ʻia i ka lāʻau ma kahi hoʻāʻo hoʻāʻo hoʻāʻo III ma Iapana.
Hāʻawi ʻia ʻo Xeomin® e Merz Pharmaceuticals GmbH i nā ʻāina ʻoi aku ma mua o 70 a hoʻohana ʻia e mālama i nā maʻi me ka spasm o luna, cervical dystonia, blepharospasm a i ʻole salivation nui.Ua hoʻopaʻa inoa ʻo Teijin Pharmaceuticals i kahi laikini kūʻokoʻa a me ka ʻaelike hoʻomohala hui no Xeomin® ma Iapana me Merz i 2017, a hoʻomaka i ke kūʻai kūʻokoʻa o Xeomin® i Dekemaba 2020 ma hope o ka loaʻa ʻana o ka ʻae mai ka Ministry of Health, Labor and Welfare (MHLW) o Iapana.Ma muli o ka hoʻokolohua lapaʻau ʻo Merz's Phase III ma Iapana, ua hoʻololi nā ʻae hou i loaʻa i kekahi o nā ʻae i ʻae ʻia.
ʻO ka maʻamau, no ka poʻe mākua, pono e hoʻokomo ʻia ʻo Xeomin® i loko o nā ʻiʻo paʻa.* ʻO ka nui o ka nui no kēlā me kēia lawelawe ʻo 400 mau ʻāpana, akā pono e hoʻemi ʻia i ka liʻiliʻi liʻiliʻi e like me ke ʻano a me ka helu o nā ʻiʻo tonic i hoʻopaʻa ʻia.Inā emi ka hopena o ka maʻa mua, e ʻae ʻia ka hana hou ʻana.He 12 mau pule a ʻoi aku paha ka lōʻihi o ka dosing, akā hiki ke hoʻopōkole ʻia i 10 mau pule ma muli o nā hōʻailona.
* Myotonic: gastrocnemius (poʻo medial, poʻo lateral), soleus, tibialis hope, flexor digitorum longus, etc.
ʻO Merz Therapeutics kahi ʻoihana o Merz Pharmaceuticals GmbH i hoʻolaʻa ʻia no ka hoʻomaikaʻi ʻana i ke ola o nā maʻi a puni ka honua.Me kāna ʻimi noiʻi ʻole, hoʻomohala a me ka moʻomeheu hou, hoʻoikaika ʻo Merz Therapeutics e hoʻokō i nā pono maʻi i kūpono ʻole a loaʻa nā hopena maikaʻi aʻe.Ke ʻimi nei ʻo Merz Therapeutics e hoʻokō i nā pono kūʻokoʻa o ka poʻe e loaʻa ana i nā maʻi neʻe, nā maʻi neurological, nā maʻi ate, a me nā kūlana olakino ʻē aʻe e hoʻopilikia nui i ka maikaʻi o ke ola o nā maʻi.Aia ʻo Merz Therapeutics ma Frankfurt, Kelemānia, me nā keʻena ʻelele ma mua o 90 mau ʻāina, a me kahi lālā ʻAmelika ʻĀkau ma Raleigh, North Carolina.ʻO Merz Pharmaceuticals GmbH he ʻāpana o ka Merz Group, kahi hui pilikino i mālama ʻia e ka ʻohana i kūpaʻa i ka hoʻomohala ʻana i nā mea hou e kūpono ana i nā pono o nā maʻi a me nā mea kūʻai aku ma mua o 110 mau makahiki.
ʻO Teijin (Tokyo Stock Exchange code: 3401) he hui honua i hoʻoikaika ʻia e ka ʻenehana e hāʻawi ana i nā hoʻonā holomua ma ke kahua o ka waiwai kaiapuni;palekana, palekana, a me ka ho'ēmi pōʻino;a me nā loli demographic a me ka hoʻonui ʻana i ka ʻike olakino.Ua hoʻokumu mua ʻia ʻo Teijin i ka makahiki 1918 ma ke ʻano he mea hana rayon mua ma Iapana, a ua hoʻomohala ʻia i kēia manawa i kahi ʻoihana kūʻokoʻa e uhi ana i ʻekolu mau ʻoihana koʻikoʻi: nā mea hana kiʻekiʻe e like me ka aramid, carbon fiber a me nā mea i hoʻohui ʻia, a me ka resin a me ka hoʻoili ʻana, Film. , polyester fiber a me ka hana huahana;mālama lapaʻau, me nā lāʻau lapaʻau a me nā lako olakino home no ka iwi / hui, ʻōnaehana hanu, a me nā maʻi cardiovascular/metabolic, kahu hānai a me ka mālama pre-symptomatic;a me IT, me nā mea lapaʻau, hui a me B2B no nā ʻōnaehana lehulehu, a me nā lako polokalamu i hoʻopaʻa ʻia a me nā lawelawe pūnaewele B2C no ka leʻaleʻa kikohoʻe.E like me ka mea i hōʻike ʻia ma ka ʻōlelo hōʻailona "Human Chemistry, Human Solutions", ua kūpaʻa ʻo Teijin i kāna mau mea kuleana a manaʻo e lilo i ʻoihana e kākoʻo ana i ka ʻoihana e hiki mai ana.Aia ka hui ma mua o 170 mau hui a he 20,000 mau limahana ma 20 mau ʻāina a puni ka honua.I ka makahiki fiscal e pau ana i ka lā Malaki 31, 2021, ua hoʻolaha ʻo Teijin i nā kūʻai hoʻohui ʻia o 836.5 biliona yen ($7.7 biliona) a me nā waiwai āpau o 1.036.4 biliona yen ($9.5 biliona).
Ka manawa hoʻouna: Sep-10-2021